GNCA News and Press, Genocea Biosciences Inc. From 04/02/19

CAMBRIDGE, Mass., April 02, 2019 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc . (NASDAQ: GNCA), a biopharmaceutical company developing neoantigen cancer immunotherapies, today announced the presentation of data from ATLAS™, its ex vivo platform for comprehensively profiling pati...

The following slide deck was published by Genocea Biosciences, Inc. in conjunction with this Read more ...

CAMBRIDGE, Mass., March 06, 2019 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing personalized cancer immunotherapies, today announced that Chip Clark, president and chief executive officer, will present a corporate overview at the Cow...

Genocea Biosciences, Inc. (GNCA) Q4 2018 Results Earnings Conference Call February 28, 2019, 09:00 AM ET Company Participants Paul Arndt - Managing Director, LifeSci Advisors Chip Clark - President and CEO Jessica Flechtner - Chief Scientific Officer Tom Davis - Chief Medical O...

Company advancing lead clinical-stage neoantigen cancer vaccine candidate and expanding pipeline into adoptive cell therapy Diantha Duvall to join as CFO, bringing broad life science financial leadership experience Conference call today at 9:00 am ET CAMBRIDGE, Mass., Feb...

InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi...

CAMBRIDGE, Mass., Feb. 21, 2019 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing personalized cancer immunotherapies, today announced that it will host a conference call and live audio webcast on Thursday, February 28 at 9:00 am ET to ...

CAMBRIDGE, Mass., Feb. 12, 2019 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing personalized cancer immunotherapies, today announced that it has entered into a private placement with certain existing and new investors providing for th...

Every decision is a kind of prediction... and every prediction, crucially, involves thinking about two distinct things: What you know and what you don't. - B. Christian & T. Griffiths, Algorithms to Live By How have stock fundamentals broken down? Were you sold a wonderful ...

Thinly traded nano cap Genocea Biosciences ( GNCA ) is up  22%  out of the gate this morning following its announcement that the first patients have been dosed in a Phase 1/2a clinical trial evaluating neoantigen cancer vaccine candidate GEN-009. More news on: Genocea Bioscie...